Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Oncolytics Biotech

Evaluate

Thumbnail
August 02, 2019

Strike two for overheated South Korean biotech

Pexa-Vec fails earlier than expected, dealing exuberant South Korean biotech investors and the oncolytic virus field another blow.

Thumbnail
October 24, 2018

Esmo 2018 – Adaptimmune gets the wooden spoon

The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.

Article image
Vantage logo
September 21, 2018

Oncolytics prepares to tap US investors

The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.

Article image
Vantage logo
September 13, 2018

Another must-have oncolytic virus asset for big pharma

Boehringer Ingelheim struck a deal with the oncolytic virus company Viratherapeutics in 2016, and it has clearly seen something extraordinary in the intervening two…

Vantage logo
February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

Vantage logo
December 13, 2016

Setbacks fail to stifle oncolytic virus business development

Vantage logo
December 08, 2016

Ash winners and losers – Bluebird and Juno set the pulses racing

Vantage logo
October 05, 2016

Interview – Boehringer beats a brave route with oncolytic virus deal

Vantage logo
April 30, 2015

Adcom puts T-Vec on track to underwhelm

Vantage logo
October 06, 2014

Acquisitions help define performance of mid and small cap stocks

Vantage logo
September 22, 2014

Still unpartnered, but now worth a lot more

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up